Global Antisense and RNAi Therapeutics Market Research Report 2023

Publisher Name :
Date: 27-Jan-2023
No. of pages: 89
Inquire Before Buying

Highlights

The global Antisense and RNAi Therapeutics market was valued at US$ 1364.1 million in 2022 and is anticipated to reach US$ 1881.9 million by 2029, witnessing a CAGR of 5.5% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Antisense and RNAi Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Antisense and RNAi Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Antisense and RNAi Therapeutics in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Antisense and RNAi Therapeutics include Tekmira Pharmaceuticals, Arbutus Biopharma, Alnylam Pharmaceuticals, Antisense Therapeutics, Silence Therapeutics, Isis Pharmaceuticals, Sirnaomics, Santaris and Roche, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Antisense and RNAi Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antisense and RNAi Therapeutics.

The Antisense and RNAi Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Antisense and RNAi Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Antisense and RNAi Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

By Company

- Tekmira Pharmaceuticals

- Arbutus Biopharma

- Alnylam Pharmaceuticals

- Antisense Therapeutics

- Silence Therapeutics

- Isis Pharmaceuticals

- Sirnaomics

- Santaris

- Roche

Segment by Type

- RNA Interference

- Antisense RNA

Segment by Application

- Hospital

- Clinic

By Region

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - UK

- - Italy

- - Russia

- - Nordic Countries

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - Southeast Asia

- - India

- - Australia

- - Rest of Asia

- Latin America

- - Mexico

- - Brazil

- - Rest of Latin America

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of MEA

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antisense and RNAi Therapeutics companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.

Global Antisense and RNAi Therapeutics Market Research Report 2023

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense and RNAi Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 RNA Interference
1.2.3 Antisense RNA
1.3 Market by Application
1.3.1 Global Antisense and RNAi Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antisense and RNAi Therapeutics Market Perspective (2018-2029)
2.2 Antisense and RNAi Therapeutics Growth Trends by Region
2.2.1 Global Antisense and RNAi Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Antisense and RNAi Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Antisense and RNAi Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Antisense and RNAi Therapeutics Market Dynamics
2.3.1 Antisense and RNAi Therapeutics Industry Trends
2.3.2 Antisense and RNAi Therapeutics Market Drivers
2.3.3 Antisense and RNAi Therapeutics Market Challenges
2.3.4 Antisense and RNAi Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antisense and RNAi Therapeutics Players by Revenue
3.1.1 Global Top Antisense and RNAi Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Antisense and RNAi Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Antisense and RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antisense and RNAi Therapeutics Revenue
3.4 Global Antisense and RNAi Therapeutics Market Concentration Ratio
3.4.1 Global Antisense and RNAi Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense and RNAi Therapeutics Revenue in 2022
3.5 Antisense and RNAi Therapeutics Key Players Head office and Area Served
3.6 Key Players Antisense and RNAi Therapeutics Product Solution and Service
3.7 Date of Enter into Antisense and RNAi Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antisense and RNAi Therapeutics Breakdown Data by Type
4.1 Global Antisense and RNAi Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Antisense and RNAi Therapeutics Forecasted Market Size by Type (2024-2029)
5 Antisense and RNAi Therapeutics Breakdown Data by Application
5.1 Global Antisense and RNAi Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Antisense and RNAi Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Antisense and RNAi Therapeutics Market Size (2018-2029)
6.2 North America Antisense and RNAi Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Antisense and RNAi Therapeutics Market Size by Country (2018-2023)
6.4 North America Antisense and RNAi Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antisense and RNAi Therapeutics Market Size (2018-2029)
7.2 Europe Antisense and RNAi Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Antisense and RNAi Therapeutics Market Size by Country (2018-2023)
7.4 Europe Antisense and RNAi Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antisense and RNAi Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific Antisense and RNAi Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antisense and RNAi Therapeutics Market Size (2018-2029)
9.2 Latin America Antisense and RNAi Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Antisense and RNAi Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Antisense and RNAi Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antisense and RNAi Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa Antisense and RNAi Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Tekmira Pharmaceuticals
11.1.1 Tekmira Pharmaceuticals Company Detail
11.1.2 Tekmira Pharmaceuticals Business Overview
11.1.3 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Introduction
11.1.4 Tekmira Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Business (2018-2023)
11.1.5 Tekmira Pharmaceuticals Recent Development
11.2 Arbutus Biopharma
11.2.1 Arbutus Biopharma Company Detail
11.2.2 Arbutus Biopharma Business Overview
11.2.3 Arbutus Biopharma Antisense and RNAi Therapeutics Introduction
11.2.4 Arbutus Biopharma Revenue in Antisense and RNAi Therapeutics Business (2018-2023)
11.2.5 Arbutus Biopharma Recent Development
11.3 Alnylam Pharmaceuticals
11.3.1 Alnylam Pharmaceuticals Company Detail
11.3.2 Alnylam Pharmaceuticals Business Overview
11.3.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Introduction
11.3.4 Alnylam Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Business (2018-2023)
11.3.5 Alnylam Pharmaceuticals Recent Development
11.4 Antisense Therapeutics
11.4.1 Antisense Therapeutics Company Detail
11.4.2 Antisense Therapeutics Business Overview
11.4.3 Antisense Therapeutics Antisense and RNAi Therapeutics Introduction
11.4.4 Antisense Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2018-2023)
11.4.5 Antisense Therapeutics Recent Development
11.5 Silence Therapeutics
11.5.1 Silence Therapeutics Company Detail
11.5.2 Silence Therapeutics Business Overview
11.5.3 Silence Therapeutics Antisense and RNAi Therapeutics Introduction
11.5.4 Silence Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2018-2023)
11.5.5 Silence Therapeutics Recent Development
11.6 Isis Pharmaceuticals
11.6.1 Isis Pharmaceuticals Company Detail
11.6.2 Isis Pharmaceuticals Business Overview
11.6.3 Isis Pharmaceuticals Antisense and RNAi Therapeutics Introduction
11.6.4 Isis Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Business (2018-2023)
11.6.5 Isis Pharmaceuticals Recent Development
11.7 Sirnaomics
11.7.1 Sirnaomics Company Detail
11.7.2 Sirnaomics Business Overview
11.7.3 Sirnaomics Antisense and RNAi Therapeutics Introduction
11.7.4 Sirnaomics Revenue in Antisense and RNAi Therapeutics Business (2018-2023)
11.7.5 Sirnaomics Recent Development
11.8 Santaris
11.8.1 Santaris Company Detail
11.8.2 Santaris Business Overview
11.8.3 Santaris Antisense and RNAi Therapeutics Introduction
11.8.4 Santaris Revenue in Antisense and RNAi Therapeutics Business (2018-2023)
11.8.5 Santaris Recent Development
11.9 Roche
11.9.1 Roche Company Detail
11.9.2 Roche Business Overview
11.9.3 Roche Antisense and RNAi Therapeutics Introduction
11.9.4 Roche Revenue in Antisense and RNAi Therapeutics Business (2018-2023)
11.9.5 Roche Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Antisense and RNAi Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of RNA Interference
Table 3. Key Players of Antisense RNA
Table 4. Global Antisense and RNAi Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Antisense and RNAi Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Antisense and RNAi Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Antisense and RNAi Therapeutics Market Share by Region (2018-2023)
Table 8. Global Antisense and RNAi Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Antisense and RNAi Therapeutics Market Share by Region (2024-2029)
Table 10. Antisense and RNAi Therapeutics Market Trends
Table 11. Antisense and RNAi Therapeutics Market Drivers
Table 12. Antisense and RNAi Therapeutics Market Challenges
Table 13. Antisense and RNAi Therapeutics Market Restraints
Table 14. Global Antisense and RNAi Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Antisense and RNAi Therapeutics Market Share by Players (2018-2023)
Table 16. Global Top Antisense and RNAi Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense and RNAi Therapeutics as of 2022)
Table 17. Ranking of Global Top Antisense and RNAi Therapeutics Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Antisense and RNAi Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Antisense and RNAi Therapeutics Product Solution and Service
Table 21. Date of Enter into Antisense and RNAi Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antisense and RNAi Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Antisense and RNAi Therapeutics Revenue Market Share by Type (2018-2023)
Table 25. Global Antisense and RNAi Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Antisense and RNAi Therapeutics Revenue Market Share by Type (2024-2029)
Table 27. Global Antisense and RNAi Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Antisense and RNAi Therapeutics Revenue Market Share by Application (2018-2023)
Table 29. Global Antisense and RNAi Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Antisense and RNAi Therapeutics Revenue Market Share by Application (2024-2029)
Table 31. North America Antisense and RNAi Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Antisense and RNAi Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Antisense and RNAi Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Antisense and RNAi Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Antisense and RNAi Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Antisense and RNAi Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Antisense and RNAi Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Antisense and RNAi Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Antisense and RNAi Therapeutics Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Antisense and RNAi Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Antisense and RNAi Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Antisense and RNAi Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Antisense and RNAi Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 46. Tekmira Pharmaceuticals Company Detail
Table 47. Tekmira Pharmaceuticals Business Overview
Table 48. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product
Table 49. Tekmira Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Business (2018-2023) & (US$ Million)
Table 50. Tekmira Pharmaceuticals Recent Development
Table 51. Arbutus Biopharma Company Detail
Table 52. Arbutus Biopharma Business Overview
Table 53. Arbutus Biopharma Antisense and RNAi Therapeutics Product
Table 54. Arbutus Biopharma Revenue in Antisense and RNAi Therapeutics Business (2018-2023) & (US$ Million)
Table 55. Arbutus Biopharma Recent Development
Table 56. Alnylam Pharmaceuticals Company Detail
Table 57. Alnylam Pharmaceuticals Business Overview
Table 58. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product
Table 59. Alnylam Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Business (2018-2023) & (US$ Million)
Table 60. Alnylam Pharmaceuticals Recent Development
Table 61. Antisense Therapeutics Company Detail
Table 62. Antisense Therapeutics Business Overview
Table 63. Antisense Therapeutics Antisense and RNAi Therapeutics Product
Table 64. Antisense Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2018-2023) & (US$ Million)
Table 65. Antisense Therapeutics Recent Development
Table 66. Silence Therapeutics Company Detail
Table 67. Silence Therapeutics Business Overview
Table 68. Silence Therapeutics Antisense and RNAi Therapeutics Product
Table 69. Silence Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2018-2023) & (US$ Million)
Table 70. Silence Therapeutics Recent Development
Table 71. Isis Pharmaceuticals Company Detail
Table 72. Isis Pharmaceuticals Business Overview
Table 73. Isis Pharmaceuticals Antisense and RNAi Therapeutics Product
Table 74. Isis Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Business (2018-2023) & (US$ Million)
Table 75. Isis Pharmaceuticals Recent Development
Table 76. Sirnaomics Company Detail
Table 77. Sirnaomics Business Overview
Table 78. Sirnaomics Antisense and RNAi Therapeutics Product
Table 79. Sirnaomics Revenue in Antisense and RNAi Therapeutics Business (2018-2023) & (US$ Million)
Table 80. Sirnaomics Recent Development
Table 81. Santaris Company Detail
Table 82. Santaris Business Overview
Table 83. Santaris Antisense and RNAi Therapeutics Product
Table 84. Santaris Revenue in Antisense and RNAi Therapeutics Business (2018-2023) & (US$ Million)
Table 85. Santaris Recent Development
Table 86. Roche Company Detail
Table 87. Roche Business Overview
Table 88. Roche Antisense and RNAi Therapeutics Product
Table 89. Roche Revenue in Antisense and RNAi Therapeutics Business (2018-2023) & (US$ Million)
Table 90. Roche Recent Development
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antisense and RNAi Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Antisense and RNAi Therapeutics Market Share by Type: 2022 VS 2029
Figure 3. RNA Interference Features
Figure 4. Antisense RNA Features
Figure 5. Global Antisense and RNAi Therapeutics Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global Antisense and RNAi Therapeutics Market Share by Application: 2022 VS 2029
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Antisense and RNAi Therapeutics Report Years Considered
Figure 10. Global Antisense and RNAi Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 11. Global Antisense and RNAi Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Antisense and RNAi Therapeutics Market Share by Region: 2022 VS 2029
Figure 13. Global Antisense and RNAi Therapeutics Market Share by Players in 2022
Figure 14. Global Top Antisense and RNAi Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense and RNAi Therapeutics as of 2022)
Figure 15. The Top 10 and 5 Players Market Share by Antisense and RNAi Therapeutics Revenue in 2022
Figure 16. North America Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 17. North America Antisense and RNAi Therapeutics Market Share by Country (2018-2029)
Figure 18. United States Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. Canada Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. Europe Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Europe Antisense and RNAi Therapeutics Market Share by Country (2018-2029)
Figure 22. Germany Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. France Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. U.K. Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Italy Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Russia Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Nordic Countries Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Asia-Pacific Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Asia-Pacific Antisense and RNAi Therapeutics Market Share by Region (2018-2029)
Figure 30. China Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Japan Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. South Korea Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Southeast Asia Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. India Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Australia Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Latin America Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Latin America Antisense and RNAi Therapeutics Market Share by Country (2018-2029)
Figure 38. Mexico Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Brazil Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Middle East & Africa Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Middle East & Africa Antisense and RNAi Therapeutics Market Share by Country (2018-2029)
Figure 42. Turkey Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Saudi Arabia Antisense and RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Tekmira Pharmaceuticals Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2018-2023)
Figure 45. Arbutus Biopharma Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2018-2023)
Figure 46. Alnylam Pharmaceuticals Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2018-2023)
Figure 47. Antisense Therapeutics Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2018-2023)
Figure 48. Silence Therapeutics Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2018-2023)
Figure 49. Isis Pharmaceuticals Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2018-2023)
Figure 50. Sirnaomics Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2018-2023)
Figure 51. Santaris Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2018-2023)
Figure 52. Roche Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2018-2023)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
  • Global RNAi for Therapeutic Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 14-Mar-2023        Price: US 3260 Onwards        Pages: 125
    RNA interference (RNAi) is a collection of small RNA directed mechanisms that result in sequence specific inhibition of gene expression. The notion that RNAi could lead to a new class of therapeutics caught the attention of many investigators soon after its discovery. The field of applied RNAi therapeutics has moved very quickly from lab to bedside. The RNAi approach has been widely used for drug development and several phase I and II clinical trials are under way. However, there are still some ......
  • Global Antisense and RNAi Therapeutics Market Research Report 2023
    Published: 27-Jan-2023        Price: US 2900 Onwards        Pages: 89
    Highlights The global Antisense and RNAi Therapeutics market was valued at US$ 1364.1 million in 2022 and is anticipated to reach US$ 1881.9 million by 2029, witnessing a CAGR of 5.5% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. North American market for Antisense and RNAi Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the fore......
  • Global RNAi for Therapeutic Market Research Report 2022 - Market Size, Current Insights and Development Trends
    Published: 24-Jan-2023        Price: US 3450 Onwards        Pages: 119
    RNA interference (RNAi) is a collection of small RNA directed mechanisms that result in sequence specific inhibition of gene expression. The notion that RNAi could lead to a new class of therapeutics caught the attention of many investigators soon after its discovery. The field of applied RNAi therapeutics has moved very quickly from lab to bedside. The RNAi approach has been widely used for drug development and several phase I and II clinical trials are under way. However, there are still some ......
  • Global Antisense and RNAi Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029
    Published: 18-Jan-2023        Price: US 3480 Onwards        Pages: 89
    According to our (Global Info Research) latest study, the global Antisense and RNAi Therapeutics market size was valued at USD 1321.4 million in 2022 and is forecast to a readjusted size of USD 1893.4 million by 2029 with a CAGR of 5.3% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. This report is a detailed and comprehensive analysis for global Antisense and RNAi Therapeutics market. Both quantitative and qualitat......
  • Global RNAi for Therapeutic Market Growth (Status and Outlook) 2023-2029
    Published: 04-Jan-2023        Price: US 3660 Onwards        Pages: 100
    RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense tec......
  • Global Targeted RNA Sequencing Market Research Report 2023
    Published: 03-Jan-2023        Price: US 2900 Onwards        Pages: 88
    Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or amplicon-based approaches, both of which enable gene expression analysis in a focused set of genes of interest, with enrichment assays also providing the ability to detect both known and novel gene fusion partners in many sample types. In the report, we......
  • Global Targeted RNA Sequencing Sales Market Report 2023
    Published: 02-Jan-2023        Price: US 4000 Onwards        Pages: 105
    Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or amplicon-based approaches, both of which enable gene expression analysis in a focused set of genes of interest, with enrichment assays also providing the ability to detect both known and novel gene fusion partners in many sample types. In the report, we......
  • Global Targeted RNA Sequencing Market 2023 by Company, Regions, Type and Application, Forecast to 2029
    Published: 01-Jan-2023        Price: US 3480 Onwards        Pages: 85
    Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or amplicon-based approaches, both of which enable gene expression analysis in a focused set of genes of interest, with enrichment assays also providing the ability to detect both known and novel gene fusion partners in many sample types. In the report, we ......
  • Global RNAi for Therapeutic Market Analysis 2017-2022 and Forecast 2023-2028
    Published: 20-Dec-2022        Price: US 2980 Onwards        Pages: 88
    Snapshot RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better th......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs